Introduction to Migraine Treatment Drugs
Migraine is a neurological condition characterised by intense headaches and can cause multiple symptoms such as vomiting, sensitivity to light and sound, nausea, fatigue and numbness. The migraine pain may start as mild, but it will become severe if not treated on time. Women are more prone to have migraines and it is related to the changes in genes that run in families. Migraine starts with the activation of trigeminal nerve which is responsible for supplying sensation to the head and face. In order to treat migraine with medication, there are two categories of drugs used, that is, drugs for acute treatment (for pain and other symptoms) and drugs for preventive treatment (to reduce severity of migraines).
Market Size and Forecast
The market for migraine treatment drugs is anticipated to record a CAGR of around 12% over the forecast period, 2020-2028. The major key factors projected to drive the growth of the market include rise in the prevalence of migraines, stressed lifestyle along with rising healthcare expenditure. Since, numbers of migraine incidences are increasing and order to meet the unmet demand in migraine drugs, most of the companies are investing in research and development areas pertaining to migraine treatment drugs. Further, novel product innovations and development of new devices for the new treatment options for migraine is anticipated to accelerate the growth of the market over the forecast period.
The treatment type is segmented into abortive treatment and preventive treatment. Based upon segmentation by treatment type, the market for abortive segment is anticipated to dominate the market on the account of ease of self administration for the people having vomiting or nausea related to migraine. In addition, abortive treatment works quickly when used at the first sign of migraine. These factors are forecasted to drive the growth of the market. CLICK TO DOWNLOAD SAMPLE REPORT
Growth Drivers
Increase in the Female Population
Migraines are more frequent in women as compared to men. This migraine in women’s is assigned to the rising and falling levels of estrogen during menstruation, menopause and pregnancy. Further, before puberty the prevalence of migraine in males and females remains same, however the first migraine in females occur when their periods begin and after puberty, it increases in females almost three times than males. Therefore, with the increase in the population of females, number of migraineurs is anticipated to increase, thus, driving the growth of the market.
Increase in Awareness regarding Migraine
The rising awareness related to migraine and the drugs available for its treatment is one of the major factors accelerating the growth of migraine treatment drugs market. A number of organisations, such as, American Headache Society, are taking measures to spread awareness related to migraine therapeutics and to provide support to the patients regarding the disorders related to headache. Moreover, financial burdens and bad environmental conditions are increasing the demand to cure stress and to aware people about mental health. Hence, awareness about migraine is estimated to drive the growth of market over the forecast period.
Restraints
Different Side Effects from Migraine Treatment Drugs
Migraine treatment includes acute therapy and preventive therapy. Since, patients want to get faster or complete relief, without any adverse affects or drugs. However, frequent use of some medications can lead to the happening of disabling condition in the patients. The side effects of the medications depend on the specific drug. Taking multiple drugs together can cause excess of serotonin in the human body leading to life threatening conditions. Hence, side effects of the migraine treatment drugs are likely to hamper the market growth over the forecast period.
Market Segmentation
Our in-depth analysis of migraine treatment drugs market includes the following segments:
By Type
- Chronic Migraine
- Episodic Migraine
By Treatment Type
- Abortive Treatment
- Triptans
- Ergot Alkaloids
- Others
- Preventive Treatment
- Topiramate
- Botulinum Toxin
- Others
By Route of Administration
- Injectable
- Nasal Sprays
- Oral
- Others
By End Users
- Hospitals
- Online Pharmacies
- Retail Pharmacies
- Others
By Region
On the basis of regional analysis, the migraine treatment drugs market is segmented into five major region including North America, Europe, Asia Pacific, Latin America and Middle East & Africa region. The market for migraine treatment drugs in North America is anticipated to dominate the market owing to its geography, increasing adoption of novel therapies and high prevalence of migraine. The Asia Pacific is projected to see significant growth in future on the account of rising demand for better healthcare services along with the contribution from the major developing economies such as India and China towards migraine treatment drugs. Moreover, large undeserved patient population and high penetration from drug manufacturers is adding up to the key factors driving the growth of the market in the region over the forecast period.
The migraine treatment drugs market is further classified on the basis of region as follows:
- North America (US and Canada) Market size, Y-O-Y growth and Opportunity analysis.
- Europe (France, Germany, Italy, Spain, UK, and Other parts of Europe) Market size, Y-O-Y growth and Opportunity analysis.
- Asia Pacific (Japan, India, China, Australia and rest of Asia Pacific) Market size, Y-O-Y growth and Opportunity analysis.
- Latin America (Mexico, Argentina and Brazil) Market size, Y-O-Y growth and Opportunity analysis.
- Middle East & Africa (Middle East, South Arabia and South Africa) Market size, Y-O-Y growth and Opportunity analysis.
Top Featured Companies Dominating the Market
- Pfizer Inc.
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Eli Lilly and Company
- Eisai Co. Ltd.
- Amneal Pharmaceuticals Inc.
- Abbott Laboratories
- Novarties International AG
- Amgen Inc.
- Teva Pharmaceuticals Industries
- Endo International Plc.
